Announced Fri, 29 May · 19:41 IST

Financial Results

Pat Growth 25pctEbitda Margin ExpansionRelated Party TransactionsResults View source PDF

PVP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+11.3%1-day move

₹26.60

prior close

₹26.44

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.9+2.1+2.0+1.7+11.3+12.2+18.6+21.6+19.1+22.3+11.5+12.1——

Up moveDown movePending

AI summary

PVP Ventures Ltd reported a turnaround in FY26 with net profit of ₹90.99 Lakhs versus a loss of ₹390.40 Lakhs in FY25. Revenue from operations nearly doubled to ₹3,292.29 Lakhs from ₹1,690.24 Lakhs. EBITDA margin expanded significantly to 72.30% from 48.89% in the prior year. However, finance costs surged over 8x to ₹3,154.31 Lakhs due to new NCD issuances of ₹15,000 Lakhs. The company completed acquisitions of Medilabs, 7Med India, and Optimus Oncology during the year. Ongoing SEBI investigations regarding related party transactions with erstwhile subsidiaries continue, and the company acknowledges compliance issues with RPT regulations under Regulation 23. Current ratio remains below 1 at 0.62, indicating negative working capital.

Likely market impact

Positive turnaround from loss to profit and strong revenue growth signal operational improvement. However, the heavy debt load (₹15,000 Lakhs NCD), negative working capital, and ongoing SEBI investigations present significant risks that could weigh on investor sentiment.